GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company specializing in vaccines and immunotherapies, announced on May 18, 2026, that it has entered into a securities purchase agreement with existing institutional investors for a private placement financing expected to yield gross proceeds of approximately $3 million. The financing, priced at-the-market under Nasdaq rules, involves the sale of 2,027,027 shares of common stock (or equivalents) along with Series A and Series B warrants to purchase up to an additional 2,027,027 shares each, both with an exercise price of $1.48 per share. The Series A warrants have a five-year term, while the Series B warrants carry an 18-month term. The closing is anticipated on or about May 19, 2026, subject to customary conditions.
The company intends to use the net proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent. The offering is being made under an exemption from registration under the Securities Act of 1933, and GeoVax has agreed to file a registration statement with the SEC covering the resale of the shares and underlying shares.
This capital infusion comes at a pivotal time for GeoVax, which is advancing several key programs. Its priority program, GEO-MVA, is a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is on an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026. This addresses critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a Phase 1/2 trial in advanced head and neck cancer and is being advanced into combination strategies, including neoadjuvant and first-line settings. Additionally, GeoVax’s pipeline includes GEO-CM04S1, a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised populations.
The financing provides GeoVax with additional runway to progress these clinical programs. For leaders in business and technology, the news underscores the continued investment in biotech innovation, particularly in vaccines and immunotherapies that address high-consequence infectious diseases and cancer. The ability to secure funding from institutional investors reflects confidence in GeoVax’s technology and regulatory strategy. The completion of a Phase 3 trial for GEO-MVA could significantly impact the global vaccine supply, especially given ongoing concerns about mpox outbreaks and biodefense needs. Similarly, advances in Gedeptin and GEO-CM04S1 could open new treatment avenues in oncology and COVID-19, respectively, potentially influencing market dynamics in these sectors.
GeoVax maintains a global intellectual property portfolio supporting its programs and continues to evaluate strategic partnerships. The company’s forward-looking statements highlight risks common to clinical-stage biotech firms, including trial outcomes, regulatory approvals, and capital requirements. However, this financing provides near-term financial stability to execute on its milestones.
For more information, visit www.geovax.com.
